EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics

René Bernards iD

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13391 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2023. Verfasst von René Bernards. Beteiligte Einrichtung: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patients with fewer side effects while at the same time reducing the cost of cancer care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsHumansClinical Trials as TopicMolecular Targeted Therapy

Stichwörter der Autor:innen

drug developmentphase 1 trialstargeted cancer drugs

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

ORCID-Profile: René Bernards

Zitieren

APA

Bernards, R. (2023). More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular Oncology. https://doi.org/10.1002/1878-0261.13391

Vancouver

Bernards R. More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular Oncology. 2023. doi:10.1002/1878-0261.13391

BibTeX
@article{Bernards2023,
  author = {Bernards, René},
  title = {More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13391}
}
Kostenlos starten →